Biome Australia Ltd (AU:BIO)
ASX:BIO
Want to see AU:BIO full AI Analyst Report?
BIO Stock Chart & Stats
AU$0.40
-AU$0.01(-1.89%)
At close: 4:00 PM EST
AU$0.40
-AU$0.01(-1.89%)
Day’s Range― - ―
52-Week RangeAU$0.27 - AU$0.63
Previous CloseN/A
Volume242.26K
Average Volume (3M)278.69K
Market Cap
AU$64.98M
Enterprise ValueAU$62.91M
Total Cash (Recent Filing)AU$3.36M
Total Debt (Recent Filing)AU$2.43M
Price to Earnings (P/E)19.7
Beta1.31
Next Earnings
Jul 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding227,998,030
10 Day Avg. Volume235,222
30 Day Avg. Volume278,692
Financial Highlights & Ratios
PEG Ratio-4.12
Price to Book (P/B)21.27
Price to Sales (P/S)5.40
P/FCF Ratio-34.81
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$1.00Price Target Upside150.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthConsistent revenue growth (16.14% year) indicates expanding product adoption and market penetration. Over 2-6 months this durable top-line momentum supports scale economies, funds commercialization and practitioner adoption efforts, and underpins sustainable expansion of distribution reach.
High Gross MarginA 61% gross margin signals pricing power and efficient product economics, giving the business a durable buffer against input cost rises. This margin structure supports investment in marketing and R&D, and provides room to absorb SG&A while maintaining structural profitability over the medium term.
Manageable LeverageModerate leverage (D/E 0.66) with positive ROE suggests a balanced capital structure that can support growth without excessive financial strain. This manageable indebtedness preserves access to credit, limits refinancing risk and provides flexibility for strategic investments or working-capital needs over coming months.
Bears Say
Negative Operating Cash FlowPersistent negative operating cash flow highlights a weakness in cash conversion despite reported profits. Over a multi-month horizon this undermines the company’s ability to self-fund inventory, marketing or capex, increases reliance on external financing, and raises execution risk if cash metrics do not improve.
Thin Net ProfitabilityA net margin near 1% shows limited translation of gross profits into retained earnings. Structurally this leaves little room for shocks or reinvestment, constrains internal funding for growth initiatives, and makes the business more sensitive to cost inflation or margin compression over the medium term.
Limited Scale / Opaque Revenue MixLack of disclosed channel breakdown and partnership detail increases concentration and execution risk. Combined with a small employee base noted elsewhere, this opacity suggests scaling constraints and potential reliance on a few channels or partners, which can impair durable growth and resilience.
Biome Australia Ltd News
BIO FAQ
What was Biome Australia Ltd’s price range in the past 12 months?
Biome Australia Ltd lowest share price was AU$0.27 and its highest was AU$0.63 in the past 12 months.
What is Biome Australia Ltd’s market cap?
Biome Australia Ltd’s market cap is AU$64.98M.
When is Biome Australia Ltd’s upcoming earnings report date?
Biome Australia Ltd’s upcoming earnings report date is Jul 28, 2026 which is in 77 days.
How were Biome Australia Ltd’s earnings last quarter?
Biome Australia Ltd released its earnings results on Feb 22, 2026. The company reported AU$0.005 earnings per share for the quarter, missing the consensus estimate of AU$0.006 by -AU$0.001.
Is Biome Australia Ltd overvalued?
According to Wall Street analysts Biome Australia Ltd’s price is currently Undervalued.
Does Biome Australia Ltd pay dividends?
Biome Australia Ltd does not currently pay dividends.
What is Biome Australia Ltd’s EPS estimate?
Biome Australia Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Biome Australia Ltd have?
Biome Australia Ltd has 227,998,030 shares outstanding.
What happened to Biome Australia Ltd’s price movement after its last earnings report?
Biome Australia Ltd reported an EPS of AU$0.005 in its last earnings report, missing expectations of AU$0.006. Following the earnings report the stock price went down -4.587%.
Which hedge fund is a major shareholder of Biome Australia Ltd?
Currently, no hedge funds are holding shares in AU:BIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Biome Australia Ltd Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$1.00 (150.00% Upside)
AU$1.00 (150.00% Upside)
Blogger Sentiment
Bullish
AU:BIO Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$63.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-34.96%
12-Months-Change
Fundamentals
Return on Equity
17.85%
Trailing 12-Months
Asset Growth
17.94%
Trailing 12-Months
Company Description
Biome Australia Ltd
Biome Australia Limited develops, commercializes, and markets various live biotherapeutics and complimentary medicines in Australia and internationally. It provides live biotherapeutic products under the Activated Probiotics brand; organic nutraceutical products under the Activated Nutrients brand; and sports performance and recovery products under the Activated X Performance brand. The company markets its products through community pharmacies and independent health practitioners. Biome Australia Limited was incorporated in 2018 and is based in Cremorne, Australia.
BIO Stock 12 Month Forecast
Average Price Target
AU$1.00
▲(150.00% Upside)
Technical Analysis
Avecho Biotechnology Limited
―
AdAlta Ltd.
―
Anatara Lifesciences Ltd
―
Bio-Gene Technology Ltd.
―
Hexima Ltd
―
Options Prices
Currently, No data available
---